Is Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) Undervalued?
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) has been on the receiving end ever since it gained regulatory approval for its Chronic Idiopathic Constipation drug, Trulance. The stock has shed more than 40% in market value over the past year, begging the question of whether the company is undervalued given Trulance’s worth.
Trulance Market Value
The drop in share value comes even as Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) continues to outline its commercial plan for Trulance that some analysts believe could be materially change the company’s fortunes. Fueling investor confidence is that the drug’s target market is constantly growing and offers few treatment alternatives.
“Synergy controls 100% of the worldwide rights to TRULANCE, a high-value asset that is now generating revenues and has secured a long lifespan that we will be able to maximize. We remain focused on having a disciplined approach to capital allocation to support appropriate investments that will ensure the long-term success of TRULANCE,” said newly appointed Chief Financial Officer Gary Gemignani.
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) business prospects with Trulance faces competition by Linzess – marketed by Allergan. While the two drugs are priced similarly, Trulance is generally agreed to have a slight edge in the marketplace.
Trulance vs. Linzess
Trulance boast of minimal side effects compared to its rival. The drug can also be taken at any time during the day, compared to Linzess which has to be taken before the first meal of the day. The growth for Trulance has been more impressive when compared to Linzess’ initial growth.
The biopharmaceutical company has already started to expand its 250-rep strong sales force as it moves to ramp up sales for Trulance.
Anlaysts will now wait to see if Trulance can help reverse Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) poor showing in the first quarter. The biopharmaceutical company says its net loss widened to (-$64.6) million, from a net loss of (-$59.9) million reported last year. Net sales in the first quarter totaled $0.1 million.
Research and development expenses in the quarter totaled $19.1 million which was a decrease from $21.2 million reported last year. The decrease has been attributed to lower spending on CIC clinical trials. Synergy Pharmaceuticals cash and cash equivalent soared to $139.3 million from $82.4 million as of December 31, 2016.
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) stock was down by 5.69% on Friday, ending the week at $3.48 a share.
I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.
About the author: Monica Gray has an undergraduate degree in Accounting and an MBA – earned with Honors. She has six years of experience in the financial markets and has been a securities analyst for the past two years.